[4 cases of osteomalacia during anticonvulsant or sedative treatment].
The authors report osteomalacia in 3 cases of epilepsy and one case of coronary heart disease treated with phenobarbitone, either alone or associated with other anticonvulsants. There were clinical signs in all cases and typical radiological signs in 3 cases, a characteristic laboratory syndrome in 4 cases. In the 3 cases where it was estimated, serum levels of parathormone were high. Finally, in 3 cases where it was measured, daily  urinary excretion of glucaric D acid was increased. The bony histological signs studied in 3 cases, were similar to those in deficiency osteomalacia. A study of Ca45 metabolism in one case, showed the characteristic changes found in osteomalacia. Finally, a study of the metabolism of tritiated vitamin D, or tritiated 25 OH CC, carried out in 3 cases, gave 3 different patterns; only one of them was characteristic of enzyme induction under the dependency of anticonvulsant. Started in 2 cases, treatment with 125 OH2CC, brought about a rapid fall in blood PTH levels which then rose again before falling progressively in one case, under treatment with 25 OH CC. The bony histological signs of hyperparathyroidism then regressed whilst serum PTH levels remained high. Phosphorous and calcium balance improved in only one case. Treatment with 25 OH CC in high dosage brought about clinical, radiological and laboratory cure of osteomalacia in both cases, reducing the frequency of fits in the epileptic patient.
D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects*; D002118:Calcium / Q000097:blood; D002762:Cholecalciferol / Q000378:metabolism; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood / Q000627:therapeutic use; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood; D010634:Phenobarbital / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects
D000927:Anticonvulsants; D006887:Hydroxycholecalciferols; D006993:Hypnotics and Sedatives; D010281:Parathyroid Hormone; D002762:Cholecalciferol; D010672:Phenytoin; D002118:Calcium; D010634:Phenobarbital
Quatre cas d'ostéomalacie au cours d'un traitement anticonvulsivant ou sédatif